To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
38 Current news of Evonikrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Evonik Industries AG and BRAIN AG co-operate in the field of the development of novelmicroorganisms with unique, selective binding- and adsorption characteristics on selected surfaces. Within the co-operation the partners pursue the joint objective of identifying and developing suitable ...
Evonik Industries is moving forward with its plans to produce Biolys®, a source of L-lysine for animal nutrition, in the OOO DonBioTech joint venture in Russia. The Evonik Executive Board has approved the realization of the project, based in Volgodonsk in Russia's Rostov region. The DonBioTech ...
Investments of approx. €350 million
Evonik plans to construct new facilities for the biotechnology production of its Biolys® feed additive (source of L-lysine) in the growth markets of South America and Eastern Europe. Work is also underway to expand the production facility at the Blair site in the U.S., with completion expected by ...
Effective immediately, Evonik Industries is increasing the prices for the products L-Ornithine-L-Aspartate, L-Proline, L-Lysine salts, L-Methionine, L-Arginine-L-Aspartate, Glycine and all other cGMP-grade amino acids. The increase amounts to 10 – 20 percents and applies globally to all new ...
The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include ...
Investment in attractive pharmaceuticals market
Evonik Industries AG has set up a new laboratory at their Hanau site for highly potent active pharmaceutical ingredients (HPAPI) and expanded their cGMP capacity for HPAPI on a kilogram scale at Tippecanoe Laboratories (Lafayette, Indiana, USA). The new laboratory allows Evonik to develop and ...
After acquisition of RESOMER business further expansion of Pharma Polymers activities
Evonik Industries AG has reached an agreement to acquire the Pharmaceuticals business of SurModics, Inc. headquartered in Eden Prairie, Minnesota, USA. Signing took place on November 1, 2011 and the transaction is expected to close shortly. Following the acquisition of the RESOMER® business from ...
Growing demand for biotechnology-manufactured L-lysine in Russia
Evonik Industries and Russian company RusBiotech International have established the joint venture Russkie Biotechnologii for manufacturing L-lysine in Russia by means of a biotechnological process. Vassily Golubev, governor of the Rostov-on-Don region, and Vadim Varshavsky, a deputy of the State ...
First additional quantities expected in November 2011
In North America, Evonik Industries is doubling its capacities for producing the feed amino acid L-lysine. The two-phase expansion of the Blair, Nebraska, plant to an annual capacity of 280,000 metric tons is on track and is expected to be completed by August 2012, six months earlier than ...
Consistent alignment of pharmaceutical business with target markets
Evonik Industries AG will combine its business in custom manufacturing of active pharmaceutical ingredients (exclusive synthesis), pharmaceutical amino acids (Rexim®) and pharmaceutical polymers in the new Health Care Business Line effective September 1, 2011. The newly formed business line will ...